CD19 and acute lymphoblastic leukemia: optimized and validated a non-viral genetic modification platform based on Sleeping Beauty transposons delivered with minicircles to express CD19 CAR and CRISPR-Cas9 ribonucleoparticles to inactivate allogeneic TCR, they demonstrated these CAR-T cells possessed vigorous antitumor activities in NALM6 (B-ALL cell) tumor-bearing mice while had significantly reduced TCR alloreactivity and GvHD development (80).